Drug intelligence / Profile preview

C21 IT

Development stage: Discontinued
Lead developer: our laboratory
Modality: Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Intraperitoneal Injection

Overview

C21 IT is a truncated diphtheria toxin DT390-based immunotoxin. It is described as an "unrelated IT" and was used as a negative control in studies evaluating the efficacy of other immunotoxins targeting cutaneous T-cell lymphoma (CTCL). Its mechanism of action involves the cytotoxic effects of diphtheria toxin, which inhibits protein synthesis.

Targets

EEF2 (Eukaryotic elongation factor 2)

Beyond the preview

Go deeper on C21 IT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C21 IT.